Atea Pharmaceuticals, Inc. (AVIR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Atea Pharmaceuticals Inc AVIR
$5.17
▲ +0.00%
(+$0.00)
Open
$5.16
Prev Close
$5.17
Day Range
$5.04 – $5.21
52W Range
$2.78 – $6.45
Market Cap
$414.66M
Beta
0.75
EPS (TTM)
$-2.09
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2020-10-30 |
| Shares Out. | 80,030,000 |
| Website | ateapharma.com/ ↗ |
| Phone | 18572048109 |
| Employees | 55 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$32.9M |
| Free Cash Flow | -$152.1M |
| Total Assets | $232.3M |
| Total Liabilities | $28.1M |
| Equity | $204.2M |
About Atea Pharmaceuticals Inc
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.
Atea Pharmaceuticals Inc is a publicly traded company under the ticker symbol AVIR on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
9 analysts (2026-09-01)